An Indian curcumin manufacturer we work with ships to three markets: São Paulo (a Brazilian nutraceutical brand), Newark (a US supplement co-manufacturer), and San José (a Costa Rican pharma company that then re-exports finished tablets across Central America). Same drum. Same lot number. Three different regulatory dossiers travel alongside it. This post is the short field guide for exporters and buyers who want to understand what changes across the three regulators, and what does not.
The one thing that is the same: the manufacturing facility
All three regulators want confidence in the same thing: the facility where the material is made. That confidence comes from a WHO-GMP or PIC/S GMP certificate issued by CDSCO (the Indian regulator). If your Indian manufacturer holds one, the substrate of every dossier is already sound. If not, no amount of paperwork downstream can substitute.
Beyond that shared baseline, each regulator asks for something slightly different, and how you package the same underlying data.
FDA (United States): the DMF is the key
The US Food and Drug Administration cares about two things at the manufacturer level: facility registration and a Drug Master File (DMF). Facility registration is free but must be renewed annually. The DMF is a confidential filing that lets the FDA reference your manufacturing process without you having to disclose it publicly. For every API and API-adjacent nutraceutical raw material, a Type II DMF gives US buyers regulatory cover.
For every food or supplement shipment, Prior Notice must be filed 8–24 hours before arrival at a US port. FDA turnaround is fast when documentation is clean; slow when a single field on the FSMA-compliant paperwork is off.
The US-specific ask is GRAS documentation for anything the buyer intends to sell as food or supplement. GRAS (Generally Recognised As Safe) status can be self-affirmed with a proper dossier. Most Indian ashwagandha and curcumin manufacturers hold this.
ANVISA (Brazil): the DMF-CEP crosswalk
Brazil's Agência Nacional de Vigilância Sanitária does not accept the US DMF directly, but it does accept EU CEP (Certificate of Suitability of Monographs of the European Pharmacopoeia). If your Indian manufacturer holds a CEP, that is your ANVISA cover. If not, ANVISA runs its own dossier evaluation, which takes longer.
ANVISA's requirement list mirrors WHO-GMP with three additions: stability data at climatic zone IV conditions (30 °C / 75 % RH, meaningful for São Paulo warehouse conditions), residual solvent panels per ICH Q3C at Brazil-relevant limits, and Portuguese-language labelling on the CoA. Registration of the finished product with ANVISA is the Brazilian importer's responsibility, but we supply the entire manufacturer dossier so they can file cleanly.
Ministerio de Salud (Costa Rica): pragmatic and thorough
Costa Rica's Ministerio de Salud runs one of the more pragmatic Central American regulatory setups. If your Indian material has WHO-GMP + CoA + heavy-metal panel + microbial profile + stability data, most of the paperwork is done. What is Costa Rica-specific: a Spanish-language technical dossier, a declaration of country of origin (India), and, for API-grade material, a reference to CDSCO's Certificate of Pharmaceutical Product (CoPP).
Costa Rica's pharma manufacturers then use the imported raw material to formulate finished doses that are re-exported across Central America under CAFTA-DR duty-free provisions. Indian raw material becomes a component of Central-American-manufactured product, and never touches the US border directly.
What we do to keep the three dossiers in sync
One CoA per batch, in English, with the analytical data that all three regulators need: HPLC assay, heavy-metal panel (Pb, As, Cd, Hg), residual solvents by GC per ICH Q3C, microbial profile per USP <61>, and moisture content. That single CoA becomes the anchor for all three regional dossiers. Spanish and Portuguese versions travel alongside for ANVISA and Ministerio de Salud filings. We handle the translation in-house. No third-party lag.
The manufacturer builds one dossier once. The exporter (us) packages it three ways, in three languages, per shipment. The buyer files one product registration per market. The regulator sees data they can verify. Nothing is duplicated except paperwork, and paperwork is the cheapest part of the chain.
— Nitik · Darsavio EXIM